Table 1.
Characteristics of the participants by vaccine dose.
| 1. vaccine N (%) | 2. vaccine N (%) | 3. vaccine N (%) | |
|---|---|---|---|
| Sex | |||
| Men | 64,849 (38) | 47,223 (36) | 20,783 (38) |
| Women | 106,159 (62) | 83,128 (64) | 34,120 (62) |
| Age | |||
| 17–25 | 10,640 (6) | 6,525 (5) | 1,779 (3) |
| 26–35 | 16,039 (9) | 11,711 (9) | 2,027 (4) |
| 36–45 | 24,558 (14) | 18,758 (14) | 6,839 (12) |
| 46–55 | 48,404 (28) | 36,863 (28) | 16,635 (30) |
| 56+ | 71,367 (42) | 56,494 (43) | 27,623 (50) |
| Vaccine type | |||
| BNT162b2 | 134,632 (79) | 110,870 (85) | 47,425 (86) |
| mRNA-1273 | 16,623 (10) | 17,914 (14) | 6,690 (12) |
| ChAdOx1-2 | 16,921 (10) | 463 (<1) | 179 (<1) |
| Other/unknown | 2,832 (2) | 1,104 (1) | 609 (1) |
| COVID-19 infection | |||
| Prior infection | 9,283 (5) | 7,216 (6) | 4,498 (8) |
| No prior infection | 146,898 (86) | 111,101 (85) | 42,220 (77) |
| Unknown | 14,827 (9) | 12,034 (9) | 8,185 (15) |